| Identification | Back Directory | [Name]
3H-Imidazo[4,5-c]pyridine-4-carboxylic acid, 5-acetyl-4,5,6,7-tetrahydro-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, [[(1-ethylpropoxy)carbonyl]oxy]methyl ester, hydrochloride (1:1) | [CAS]
190602-72-3 | [Synonyms]
TA-606 free
3H-Imidazo[4,5-c]pyridine-4-carboxylic acid, 5-acetyl-4,5,6,7-tetrahydro-2-propyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, [[(1-ethylpropoxy)carbonyl]oxy]methyl ester, hydrochloride (1:1) | [Molecular Formula]
C33H40ClN7O6 | [MOL File]
190602-72-3.mol | [Molecular Weight]
666.18 |
| Hazard Information | Back Directory | [Description]
TA-606, also known as TA-606 free, is an angiotensin type 1 receptor antagonist potentially for the treatment of hypertension. TA-606 was immediately converted to its active form, 606A, after oral administration, and it demonstrated potent inhibition of the Ang II-induced pressor response in conscious normotensive dogs. It also had a potent hypotensive effect in conscious 2K,1C-renal hypertensive dogs. These effects of TA-606 were 32 and 30 times more potent than those of losartan, respectively. In addition, EXP3174, an active metabolite of losartan, but not 606A showed an orthostatic hypotensive effect in the rat tilting model. | [Uses]
TA-606 is a potent and orally active angiotensin II-receptor antagonist. TA-606 shows antihypertensive efficacy. TA-606 can be used for hypertension research[1]. | [in vivo]
TA-606 dose-dependently reduces blood pressure at doses of ≥0.03 mg/kg, p.o., and the effect is sustained ≥10 h after the oral administration in hypertensive rats[1]. | [IC 50]
AT2 Receptor | [References]
[1] Hashimoto Y, et al. Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat. J Cardiovasc Pharmacol. 1998 Apr;31(4):568-75. DOI:10.1097/00005344-199804000-00015 |
|
|